• Je něco špatně v tomto záznamu ?

Aberrant p27Kip1 promoter methylation in malignant melanoma

J Worm, J Bartkova, AF Kirkin, P Straten, J Zeuthen, J Bartek, P Guldberg

. 2000 ; 19 (44) : 5111-5115.

Jazyk angličtina Země Anglie, Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc14081278
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do 2004
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Medline Complete (EBSCOhost) od 1997-01-09 do 2015-11-26
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

p27Kip1 is a regulator of the mammalian cell cycle and a putative tumor suppressor. Distinct altered patterns of p27Kip1 protein expression are found in a variety of human carcinomas, and p27Kip1 expression levels usually correlate directly with disease-free survival. The mechanism(s) by which p27Kip1 expression is reduced or lost during tumorigenesis remains unclear. Specific alterations of the p27Kip1 gene, including mutations and homozygous deletions, are exceedingly rare in human cancers. We have used methylation-specific PCR and bisulfite genomic sequencing to examine the methylation status of p27Kip1 in 61 primary and metastatic tumors and 35 cell lines from patients with malignant melanoma. Dense methylation of a CpG island in the promoter region of p27Kip1 was detected in four of 45 metastatic tumors (9%) and three of the cell lines (9%), including two cell lines established from two different metastases from the same patient. Examination of a naturally occurring, allele-specific sequence variant demonstrated that p27Kip1 methylation is associated with transcriptional silencing in situ. Cell lines with p27Kip1 methylation showed retention of the wild-type allele and detectable p27Kip1 protein whose abundance was reduced compared with normal melanocytes. Collectively, our data suggest that DNA methylation may be a cause of monoallelic p27Kip1 silencing in malignant melanoma, which would support a role for p27Kip1 haploinsufficiency in human cancer.

000      
00000naa a2200000 a 4500
001      
bmc14081278
003      
CZ-PrNML
005      
20141203205023.0
007      
ta
008      
141203s2000 enk f 000 0|eng||
009      
AR
035    __
$a (PubMed)11042700
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Worm, J. $u Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark.
245    10
$a Aberrant p27Kip1 promoter methylation in malignant melanoma / $c J Worm, J Bartkova, AF Kirkin, P Straten, J Zeuthen, J Bartek, P Guldberg
520    9_
$a p27Kip1 is a regulator of the mammalian cell cycle and a putative tumor suppressor. Distinct altered patterns of p27Kip1 protein expression are found in a variety of human carcinomas, and p27Kip1 expression levels usually correlate directly with disease-free survival. The mechanism(s) by which p27Kip1 expression is reduced or lost during tumorigenesis remains unclear. Specific alterations of the p27Kip1 gene, including mutations and homozygous deletions, are exceedingly rare in human cancers. We have used methylation-specific PCR and bisulfite genomic sequencing to examine the methylation status of p27Kip1 in 61 primary and metastatic tumors and 35 cell lines from patients with malignant melanoma. Dense methylation of a CpG island in the promoter region of p27Kip1 was detected in four of 45 metastatic tumors (9%) and three of the cell lines (9%), including two cell lines established from two different metastases from the same patient. Examination of a naturally occurring, allele-specific sequence variant demonstrated that p27Kip1 methylation is associated with transcriptional silencing in situ. Cell lines with p27Kip1 methylation showed retention of the wild-type allele and detectable p27Kip1 protein whose abundance was reduced compared with normal melanocytes. Collectively, our data suggest that DNA methylation may be a cause of monoallelic p27Kip1 silencing in malignant melanoma, which would support a role for p27Kip1 haploinsufficiency in human cancer.
590    __
$a bohemika - dle Pubmed
650    02
$a substituce aminokyselin $7 D019943
650    12
$a proteiny buněčného cyklu $7 D018797
650    02
$a CpG ostrůvky $x fyziologie $7 D018899
650    02
$a inhibitor p27 cyklin-dependentní kinasy $7 D050760
650    12
$a metylace DNA $7 D019175
650    02
$a regulace genové exprese u nádorů $x genetika $7 D015972
650    02
$a umlčování genů $7 D020868
650    02
$a lidé $7 D006801
650    02
$a melanocyty $x metabolismus $7 D008544
650    12
$a melanom $x genetika $x metabolismus $7 D008545
650    12
$a proteiny asociované s mikrotubuly $x genetika $x metabolismus $7 D008869
650    02
$a mutace $7 D009154
650    02
$a polymerázová řetězová reakce $7 D016133
650    02
$a promotorové oblasti (genetika) $x genetika $7 D011401
650    02
$a messenger RNA $x biosyntéza $x genetika $7 D012333
650    02
$a aktivace transkripce $7 D015533
650    12
$a nádorové supresorové proteiny $7 D025521
700    1_
$a Bártková, Jiřina $7 xx0094304
700    1_
$a Kirkin, A.F.
700    1_
$a Straten, P.
700    1_
$a Zeuthen ,J.
700    1_
$a Bártek, Jiří, $d 1953- $7 xx0046271
700    1_
$a Guldberg, P.
773    0_
$t Oncogene $x 0950-9232 $g Roč. 19, č. 44 (2000), s. 5111-5115 $p Oncogene $w MED00003600
773    0_
$p Oncogene $g 19(44):5111-5, 2000 Oct 19 $x 0950-9232
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20141203205019 $b ABA008
991    __
$a 20141203205019 $b ABA008
999    __
$a ok $b bmc $g 1049586 $s 880337
BAS    __
$a 3
BMC    __
$a 2000 $b 19 $c 44 $d 5111-5115 $x MED00003600 $i 0950-9232 $m Oncogene $n Oncogene
LZP    __
$a NLK 2014-1/lp

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...